Figure 1
Figure 2
Pulmonary function and ACT score after treatment 1 and 2 months
| Variables | Baseline | 4th week | 8th week |
|---|---|---|---|
| FEV1 | 1.99 + 0 56 | 2.20 + 0 64 P < 0.001 vs. baseline, | 2.36 + 0 58 P < 0.001 vs. baseline, |
| FVC | 2.84 + 0.74 | 3.05 + 0.81 P < 0.05 vs. baseline | 3.13 + 0.82 P < 0.001 vs. baseline, |
| PEF | 338.64 + 109.60 | 365.0 + 103.0 P < 0.05 vs. baseline | 399.47 + 101.79 P < 0.001 vs. baseline, |
| ACT | 16.36 + 3.97 | 20.82 + 3.30 P < 0.001 vs. baseline, | 23.00 + 1.69 P < 0.001 vs. baseline, |
Gender differences and the improvement of pulmonary function and ACT score after treatment
| Variables | Baseline | 4th week | 8th week |
|---|---|---|---|
| FEV1 (L) | |||
| Male | 2.20 + 0.48 | 2.46 + 0.50 P < 0.001 vs. baseline, | 2.55 + 0.49 P < 0.001 vs. baseline, |
| Female | 1.74 + 0.52 | 1.91 + 0.61 P < 0.05 vs. baseline | 2.05 + 0.51 P < 0.05 vs. baseline |
| FVC (L) | |||
| Male | 3.21 + 0.63 | 3.41 + 0.68 | 3.46 + 0.71 P < 0.05 vs. baseline |
| Female | 2.43 + 0.56 | 2.68 + 0.70 P < 0.05 vs. baseline | 2.75 + 0.60 P < 0.001 vs. baseline, |
| PEF (L/min) | |||
| Male | 378.33 + 79.07 | 403.33 + 78.89 P < 0.05 vs. baseline | 430.83 + 68.02 P < 0.001 vs. baseline, |
| Female | 295.83 + 114.85 | 322.50 + 103.14 P < 0.05 vs. baseline | 341.67 + 104.26 P < 0.001 vs. baseline, |
| ACT score | |||
| Male | 17.08 + 3.29 | 21.67 + 1.92 P < 0.001 vs. baseline, | 23.42 + 1.31 P < 0.001 vs. baseline, |
| Female | 15.50 + 4.66 | 20.08 + 4.03 P < 0.001 vs. baseline, | 22.83 + 1.85 P < 0.001 vs. baseline, |
Baseline characteristics
| Characteristic | Value (%) |
|---|---|
| Number of patients | 24 |
| Male sex, no (%) | 12 (50) |
| Age, years | |
| mean ± SD | 51.92 ± 10.71 |
| range | 31-70 |
| Male age, year | 53.17 ± 10.95 |
| Female age, year | 50.67 ± 10.78 |
| Body mass index, kg/m2 | 22.07 ± 4.79 |
| Symptomatic GERD, no (%) | 18 (75) |
| regurgitation | 18 (100) |
| heartburn | 15 (83) |
| chest pain | 13 (72) |
| chronic cough | 10 (55) |
| hoarseness | 8 (44) |
| Asthma control status, no (%) | |
| partly controlled | 18 (75) |
| uncontrolled | 6 (25) |
| Medication, no (%) | |
| SABA+ICS | 7 (29) |
| SABA+LABA/ICS | 12 (50) |
| SABA+LABA/ICS+theophylline | 4 (17) |
| SABA+LABA/ICS+theophylline+antileukotriene | 1 (4) |
| Coexisting conditions, no (%) | |
| allergic rhinitis | 8 (33) |
| hypertension | 6 (25) |
| avascular necrosis | 1 (4) |
| diabetes mellitus | 3 (12) |
| benign prostate hypertrophy | 1 (4) |
| dyslipidemia | 3 (13) |
| ACT score, no (%) | |
| 20-24 | 8 (33) |
| <20 | 16 (67) |
| Smoking status | 0 (0) |